Doxycycline is not routinely recommended for most urinary tract infections (UTIs), despite evidence that it can act against some bacteria responsible for the infections. Its use depends on the organism causing the infection and whether laboratory testing shows that it is susceptible to the drug.
The Infectious Diseases Society of America (IDSA), in its guidance on antimicrobial-resistant infections, advises against using doxycycline to treat uncomplicated bladder infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), citing limited evidence of clinical effectiveness and the drug’s relatively limited excretion into urine. The guidance notes that older studies of oral tetracyclines provide insufficient evidence to support their routine use for these infections.
UTIs occur when bacteria enter and multiply in the urinary tract. They can affect the bladder, urethra or kidneys, with symptoms varying according to the site and severity of the infection.
Common symptoms include pain or burning during urination, frequent urination and a persistent urge to pass urine. Fever, pain in the side or back, and other systemic symptoms may indicate a more serious infection requiring prompt medical assessment.
How treatment is selected
Doxycycline belongs to the tetracycline class of antibiotics. It works by interfering with bacterial protein production, a process bacteria need to grow and multiply.
However, its activity against certain bacteria does not automatically make it a suitable treatment for every infection those organisms can cause. The drug’s ability to reach the site of infection, the bacteria’s susceptibility and the patient’s clinical condition all influence treatment decisions.
For uncomplicated lower UTIs, commonly recommended antibiotics include nitrofurantoin, trimethoprim and fosfomycin, depending on the patient and applicable clinical guidance. The UK’s National Institute for Health and Care Excellence (NICE) recommends considering previous urine culture results, antibiotic exposure and local resistance patterns when selecting treatment.
Where symptoms persist or worsen despite treatment, clinicians may review the diagnosis, obtain a urine culture and change the antibiotic according to the laboratory findings.
The IDSA’s 2025 guidance on complicated UTIs also recommends considering the severity of illness, previous resistant infections, patient-specific factors and relevant resistance data when selecting antibiotics. For confirmed infections, treatment should be adjusted to the identified organism and its susceptibility results when available.
Risks and precautions
Like other antibiotics, doxycycline can cause side effects. These may include nausea, diarrhoea and increased sensitivity to sunlight. Patients should follow the instructions provided by their healthcare professional and seek advice if they experience concerning reactions.
Antibiotic use can also increase the risk of infection with Clostridioides difficile, commonly known as C. diff. The bacterium can cause diarrhoea and inflammation of the colon, sometimes leading to severe complications.
The US Centers for Disease Control and Prevention advises people who develop diarrhoea during or after antibiotic treatment to contact a healthcare professional for assessment. Severe diarrhoea, fever or significant abdominal pain warrants prompt medical attention.
Doxycycline is not appropriate for every patient. Pregnancy, breastfeeding, age and other medicines may affect the choice of treatment, so a healthcare professional should assess its suitability before prescribing it.
Why urine testing matters
A urine culture can identify the bacteria responsible for an infection, while susceptibility testing helps determine which antibiotics are likely to work.
These tests are particularly useful when an infection is complicated, symptoms persist, resistance is suspected or previous treatment has failed. They can help clinicians avoid unnecessary antibiotic changes and select treatment more precisely.
Doxycycline may have a role in selected cases when laboratory results and clinical assessment support its use. It should not, however, be treated as a routine second-line option for all UTIs simply because another antibiotic has failed.
